A randomized, open-label, multicentre, comparative study of therapeutic efficacy, safety, and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb, in the treatment of mild forms of COVID-19

Abstract Background COVID19 is a high burden for medicine and society as still no specific therapy exists. Most patients depend on symptomatic treatment, comparable to the treatment in common respiratory infection e.g., Acetaminophen or Ibuprofen. Many cases of show mild forms without need hospitalization. In this randomized, open-label, multicentre, comparative trial we analysed efficacy, safety, tolerability herbal medicinal product BNO 1030 COVID-19 offer an additional relive. Methods The study was designed open label prospective, multicentred clinical trial. Out 133 screened outpatients aged 18 70 with symptoms 120 were randomised (1:1) 2 parallel groups. main group received addition (acetaminophen ibuprofen). control got only. laboratory proven COVID 19 included final analyses: 47 – 46 one. evaluation criteria dynamics symptoms: hyperthermia, myalgia, nasal congestion, discharge, coughing, anosmia, rhinolalia, sore throat, duration use antipyretics (clinically significant fever). These assessed during physician’s visit 4-point scale (0 — absent, 1 insignificant, moderate, 3 strong/pronounced) self- via ten-point visual analogue (VAS) daily patient’s diary. primary endpoint decrease average score compared baseline defined “therapeutic benefit” from usage 1030. Results comparison both groups over time, ( n = 47) showed greater severity fever, anosmia by doctor V2 (4th day) V3 (14th those V1, well reduction intake p < 0.05). Significant differences obtained, too, based results self-assessment patient. benefit days. There increase number recovered 73.9–96.6 % according symptom score, hospitalized 8.6–4.4 group., data All tolerated well, adverse drug reactions being reported. Conclusions (Imupret®) offers safe effective diagnosed 18–70 acetaminophen NSAIDs. positive treated Imupret earlier relive when Trial registration This registered ClinicalTrial.gov: NCT04797936 .